Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Avalo Therapeutics, Inc. (CERC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/14/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SECOND FORBEARANCE AGREEMENT"
08/08/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/07/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "AMENDMENT NO. 1 TO SALES AGREEMENT",
"Wyrick Robbins Yates & Ponton LLP 4101 Lake Boone Trail, Suite 300"
08/03/2023 8-K Quarterly results
Docs: "Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates"
07/21/2023 8-K Quarterly results
06/02/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK",
"[SIGNATURE PAGE FOLLOWS&#93"
05/04/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
04/21/2023 8-K Quarterly results
03/29/2023 8-K Quarterly results
03/13/2023 8-K Investor presentation
Docs: "FOR DISCUSSION PURPOSES ONLY Avalo Therapeutics, Inc. March 2023 Corporate Presentation"
02/03/2023 8-K Quarterly results
01/17/2023 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/07/2022 8-K Quarterly results
Docs: "Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates"
08/16/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates"
08/01/2022 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 to Apollo Therapeutics"
07/22/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/16/2022 8-K Investor presentation
Docs: "Innovation Driven by Compassion March 2022 Corporate Presentation EX-99.1"
03/02/2022 8-K Quarterly results
02/18/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Avalo Therapeutics Announces Leadership Transition"
02/08/2022 8-K Quarterly results
01/06/2022 8-K Investor presentation
Docs: "Innovation Driven by Compassion January 2022 Investor Day Presentation",
"Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event"
12/15/2021 8-K Quarterly results
12/06/2021 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "Avalo Reports Third Quarter 2021 Financial Results and Provides Business Updates"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy